EP121: Cardiac Rehabilitation With Dr. Alistair Begg Part 3

Welcome to my podcast. I am Doctor Warrick Bishop, and I want to help you to live as well as possible for as long as possible. I’m a practising cardiologist, best-selling author, keynote speaker, and the creator of The Healthy Heart Network. I have over 20 years as a specialist cardiologist and a private practice of over 10,000 patients. Podcast Summary Introduction Dr. Warrick Bishop, a practicing cardiologist and passionate health educator, hosts this episode featuring Dr. Alistair Begg, a cardiologist from Adelaide specializing in cardiac rehabilitation. The episode focuses on blood pressure management and diabetes as critical risk factors in cardiac rehabilitation, exploring how these conditions affect heart health and discussing emerging treatment approaches. Key Takeaways: Cardiac rehabilitation is a holistic, patient-centered journey that aims to identify the causes of cardiac events and guide patients toward optimal long-term health through education and lifestyle modification. Blood pressure is the single biggest treatable risk factor for cardiovascular disease, with target levels typically around 130/80 mmHg, or 120/70 mmHg for younger patients without diabetes. Office blood pressure measurements often inaccurately reflect a patient's true blood pressure due to "white coat syndrome," making out-of-office measurements and 24-hour blood pressure monitors essential for accurate assessment. High blood pressure causes structural changes to the heart and significantly increases the risk of atrial fibrillation and heart failure, which have now become the leading causes of cardiac hospitalization, surpassing heart attacks. Diabetes is a serious cardiovascular risk factor that makes heart disease harder to treat, leads to more complications, and results in worse outcomes compared to non-diabetic patients. Prevention of diabetes through weight management, regular physical activity, and healthy diet is critical, and blood sugar should be monitored regularly by healthcare providers. Sodium-glucose transport inhibitors (SGLT2 inhibitors) are an exciting new class of drugs that prevent kidney reabsorption of glucose and have shown remarkable benefits in preventing heart failure and improving outcomes in both diabetic and non-diabetic patients. The DAPA-HF trial demonstrated that SGLT2 inhibitors provide equal cardiac benefits for both diabetic and non-diabetic patients with heart failure, opening new therapeutic frontiers in cardiology. Clinical experience with SGLT2 inhibitors has been very favorable, with patients experiencing fewer hospital visits and improved cardiac function beyond what the evidence base alone would suggest.